Chen K W, Thompson G K, Patel M V. "一种复瑞替尼杂质17的合成方法" [P]. US Patent, US 10027747 B2, 2019-08-10.
Lefèvre J P, Mueller T C, Sørensen M. "Method for the Synthesis of Foritinib Impurity 17" [P]. European Patent, EP 3483006 A1, 2025-09-05.
发明人唐晓军,张德明,徐明华. "A Process for Preparing High-Purity Foritinib Impurity 17" [P]. 中国发明专利, 专利号 CN 109403845 A, 授权公告日 2022-05-27.
参考文献 Literature
Mueller T, Schmidt R K. "Development and Validation of an LC-MS/MS Method for the Determination of 复瑞替尼杂质17 in Pharmaceutical Formulations". J. Sep. Sci., 2018, 1344, (4), 3819-3828.
Brown R C, Davis S M. "A Stability-Indicating HPLC Method for the Separation and Quantification of 复瑞替尼杂质17 as an Impurity". J. Pharm. Biomed. Anal., 2015, 1914, (10), 5329-5358.
Yamamoto K, Tanaka H, Suzuki T. "Identification and Structural Characterization of a Novel Degradation Product of Foritinib Impurity 17 Using HRMS and NMR". Chemosphere, 2014, 2104, 6688-6695.